Novo Nordisk set to restructure R&D business
Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmark and China. It is done so that the expansion is accelerated and its pipeline across serious chronic diseases is diversified. Novo ruminates to have four “Transformational Research Units” in place that will be concentrated on finding new therapies and technologies. Also, the drug maker apprised regarding investment that it will be done more in automation, machine learning and artificial intelligence to accelerate drug discovery, laboratory infrastructure and information technology, so to make R&D more efficient.